mRCC Patient Selection for Ipilimumab/Nivolumab

(7:36)

Therapy Selection for Patients With Newly Diagnosed mRCC

(4:5)

Dr. McKay on Statin Use in Patients With mRCC

(1:14)

Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCC

(50)

More mRCC Patients Receiving Treatment

(1:17)

mRCC: How an Approved I-O Regimen Impacts Treatment

(4:18)

mRCC: Cytoreductive Nephrectomy in the Modern Era

(10:54)

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

(7:55)

Patient Factor Consideration for Treatment of mRCC

(7:1econd)

The ECOG-ACRIN E2810 study: pazopanib for patients with mRCC

(1:20)

Deferred Therapy for Favorable-Risk mRCC Patients

(7:43)

Nephrectomy after complete response to immune checkpoint inhibitors for mRCC

(5:34)

Treatment patterns in mRCC patients - Video Abstract ID 148917

(2:1econd)

Pilot Study of Tremelimumab With or Without Cryoablation in Patients with mRCC

(10:48)

mRCC: When is TKI/I-O Combination Therapy Appropriate?

(9:5)

Dr. Figlin on Intermediate Prognosis Patients With mRCC

(1:4)

First-line therapy options in mRCC

(2:3)

Managing Patients on Lenvatinib/Everolimus in mRCC

(3:39)

Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

(7:4)

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

(1:25)